UBS Reiterates Buy Rating on Gilead Sciences (GILD) Following ACLX Acquisition Announcement
Tweet Send to a Friend
UBS analyst Michael Yee reiterated a Buy rating and $175.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst commented, "GILD ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
